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Abstract:
Background:
A Perioperative Surgical Home (PSH) care model applies a standardized multidisciplinary approach to patient care using evidence-
based medicine to modify and improve protocols. Analysis of patient outcome measures, such as postoperative nausea and vomiting
(PONV), allows for refinement of existing protocols to improve patient care. We aim to compare the incidence of PONV in patients
who underwent primary total joint arthroplasty before and after modification of our PSH pain protocol.
Methods:
All total joint replacement PSH (TJR-PSH) patients who underwent primary THA (n=149) or TKA (n=212) in the study period were
included.  The modified protocol  added a single dose of  intravenous (IV) ketorolac given in the operating room and oxycodone
immediate release orally instead of IV Hydromorphone in the Post Anesthesia Care Unit (PACU). The outcomes were (1) incidence
of PONV and (2) average pain score in the PACU. We also examined the effect of primary anesthetic (spinal vs.  GA) on these
outcomes. The groups were compared using chi-square tests of proportions.
Results:
The  incidence  of  post-operative  nausea  in  the  PACU  decreased  significantly  with  the  modified  protocol  (27.4%  vs.  38.1%,
p=0.0442). There was no difference in PONV based on choice of anesthetic or procedure. Average PACU pain scores did not differ
significantly between the two protocols.
Conclusion:
Simple modifications to TJR-PSH multimodal  pain management protocol,  with decrease in IV narcotic  use,  resulted in a  lower
incidence  of  postoperative  nausea,  without  compromising  average  PACU  pain  scores.  This  report  demonstrates  the  need  for
continuous monitoring of PSH pathways and implementation of revisions as needed.
Keywords: Multimodal pain management, Narcotics, Opioids, Perioperative surgical home, Postoperative nausea and vomiting,
Total joint replacement.
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INTRODUCTION
Postoperative nausea and vomiting (PONV) is a common and disturbing problem for patients. In the first 24 hours
after surgery the rates of nausea and vomiting are approximately 52% and 25% respectively [1]. Furthermore the risk of
nausea after joint replacement surgery is 61% with 42% vomiting, as found by Koivuranta et al. [1]. Many risk factors
predisposing  to  PONV  in  adults  have  been  studied  and  in  the  high  risk  population,  79%  of  these  patients  may
experience  PONV [2].  Risk  factors  for  PONV include:  female  sex,  non-smokers,  younger  age,  general  anesthesia,
volatile anesthetics and nitrous oxide, and duration of anesthetic [2, 3]. Postoperative opioids were also found as an
individual risk factor for PONV [2, 3].
In addition to the high incidence of PONV and the distress it causes to patients, PONV is associated with economic
implications  for  overall  health  care  costs.  Patients  with  unresolved  PONV  may  require  extended  stays  in  the
postoperative anesthesia care unit (PACU), increased total length of stay [4] and increased burden on the health care
system [5,  6].  By  reducing  PONV,  patients  are  able  to  mobilize  earlier  and  facilitate  an  early  active  rehabilitation
protocol [7]. Enacting measures to reduce PONV was shown to significantly reduce associated health care costs while
improving quality of care for the patients [4, 7, 8]. Recently, the use of peri-articular local anesthetic (PAI) blocks in
total joint arthroplasty has increased. PAI techniques are simple to perform, and are associated with lower incidence of
PONV outcomes when compared to general anesthetic [8] or postoperative epidural analgesia alone [9].
Using a Perioperative Surgical Home (PSH) care model, patient care is standardized throughout the perioperative
course.  This  study  is  aimed  to  compare  the  incidence  of  PONV  in  patients  who  underwent  primary  total  knee
arthroplasty (TKA) and total hip arthroplasty (THA) before and after modification of our PSH based multimodal pain
protocol. We hypothesized that substituting IV opioid with other medications in the PACU would lead to a decrease in
PONV without an increase in reported pain scores.
MATERIALS AND METHODS
The institutional review board approved this study. We conducted a retrospective chart  review of prospectively
gathered data. All primary Total Joint Replacement (THA and TKA) patients between October 2012 and December
2014  were  included.  A  total  of  149  primary  total  hip  arthroplasty  (THA)  procedures  and  212  primary  total  knee
arthroplasty (TKA) procedures were included.
A standard multimodal pain protocol was studied from October 2012 to April 2014 and is presented in Fig. (1).
Subsequently, the modified multimodal pain protocol was implemented in May 2014 with the purpose of reducing the
incidence of PONV in this population (Fig. 1). The changes in the protocol included an additional single dose of IV
ketorolac (15mg) given at the end of surgery in the Operating Room (OR) and postoperative oxycodone (immediate
release 5-10mg orally) as needed for pain control instead of IV hydromorphone in the Postoperative Anesthesia Care
Unit (PACU) (Fig. 1).
The primary outcome was incidence of post-operative nausea and vomiting in the PACU and was measured by the
PACU nurse in hourly intervals  as  long as  the patients  were treated in the PACU. Secondary outcomes were post-
operative average pain scores in the PACU, which were measured with a 10cm Visual Analog Scale (VAS) for pain
recorded by the PACU nurse at the same time intervals as PONV assessment. Additionally, this study examined the
effect of primary anesthetic modality (spinal vs. general anesthesia) on PONV and VAS pain score outcomes.
Statistical Analysis
Scalar variables are reported as mean ± standard deviation and were compared using t-test. Categorical variables
were  compared  using  χ2.  Significance  level  was  set  at  0.05  and  confidence  intervals  (CI)  are  reported  at  the  95th
percentile. IBM® SPSS® 21 for windows was used for all analyses (IBM, Armonk, NY, USA).
RESULTS
There were no significant differences between the study groups regarding age, BMI gender or ASA classification
(Table  1).  The incidence of  nausea in  the PACU decreased significantly  in  the patients  who received the modified
protocol (27.4%) compared to the original protocol cohort (38.1%), (p=0.0442, CI of difference -20.8% to -0.6%). The
rate of vomiting was 15.4% under the original protocol,  and 14.3% under the modified protocol,  a non-statistically
significant  difference  (p=0.371).  There  was  no  difference  in  the  rates  of  nausea  or  vomiting  based  on  choice  of
anesthetic (spinal  vs.  general,  p=0.67) or arthroplasty procedure performed (TKA vs.  THA p=0.76).  Fig.  (2)  shows
Effects of Modification of Pain Protocol The Open Orthopaedics Journal, 2016, Volume 10   507
nausea rates in each procedure group before and after the protocol change. Average PACU pain scores were lower with
the modified protocol when compared to the original protocol but the difference was not statistically significant (1.7
±2.6 and 2.0 ±2.4 respectively p=0.15) (Fig 3).
Fig. (1). Total joint replacement perioperative surgical home multimodel pain management protocol.
Fig. (2). Proportion of patients with nausea by group.
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Fig. (3). Boxplots of PACU pain score before and after protocol change.
Fig. (4). Recovery room opioid dose by group.
Table 1. Patient demographics between the pre-modification group (original), and the post-modification (modified) group.
 Modified Original
  p
n=117 n=245
Age 64.1 ± 12.8 63.5 ± 14.1 0.69
BMI 29.2 ± 6.2 29.6 ± 6.4 0.58
Gender (M) 45% 36% 0.11
ASA
I 0% 0% 0.211
II 27% 19%
III 72% 75%
IV 1% 5%
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Recovery room opioid use was classified as no use, low use (1 administration), moderate use (2-3 administrations)
and high use (4+ administrations). The modified protocol group had a higher percent of patients who did not require any
PACU opioids and fewer patients who used low, moderate and high dose opioids, this result did not reach significance
(Fig 4).
DISCUSSION
The primary outcome of this study reports decreased incidence of postoperative nausea without changes in PACU
VAS pain scores. This effect was observed after simple modifications to our total joint replacement PSH multimodal
pain management protocol. The modifications entailed adding 15mg IV Ketorolac at the end of surgery and replacing
IV Hydromorphone in the PACU with oral immediate release Oxycodone (5-10mg).
IV narcotic use is known to be associated with increased PONV. The decreased postoperative nausea observed in
this  study  may  be  partially  due  to  replacing  PACU  hydromorphone  with  oxycodone.  The  benefits  of  decreased
postoperative nausea must be weighted against a possible increase in postoperative patient reported pain scores. In this
study there was no associated increase in postoperative VAS pain scores with a decrease in morphine consumption.
Based on these results the TJR-PSH modified protocol proved superior to the original protocol.
PONV remains of concern after TJR as it may predispose to decreased mobility, aspiration, electrolyte imbalances,
thromboembolic disease, emotional distress, discomfort, and longer hospital stays [10]. Many antiemetic interventions
to prevent PONV were shown to be similarly effective [8]. However, it is preferable to avoid nausea and vomiting than
to treat them after presentation. Thus, the safest  and least  expensive prophylaxis should be utilized first  [8].  In our
modified TJR-PSH protocol this principal is employed by removing a high risk drug (IV hydromorphone) in an attempt
to utilize fewer narcotic medications while maintaining adequate postoperative pain control and reducing PONV.
Ketorolac is a non-selective COX inhibitor indicated for acute moderately severe pain management. By decreasing
formation of prostaglandin precursors ketorolac is known to have an antipyretic, analgesic and anti-inflammatory effect.
The recommended dose of ketorolac is 120 mg per day or less for 5 days or less [11]. Contraindications to use are the
same as for other NSAIDs. NSAID drugs are often associated with both gastrointestinal bleeding and operative sight
bleeding. However,  Storm et al.  [12] found that  the overall  associations between ketorolac use and gastrointestinal
bleeding and operative site bleeding are small. Physicians should however limit the dose and length of ketorolac use in
older subjects.
Many total joint arthroplasty protocols use Ketorolac postoperatively in the ward or as part of the peri-articular
injection  cocktail  [13  -  16].  Parvtaneni  et  al.  [13]  used  peri-articular  injections  with  a  multimodal  protocol  that
employed postoperative ketorolac and found excellent pain control and functional recovery compared to conventional
pain control modalities. Pagnano et al. [14] has used Ketorolac for breakthrough pain postoperatively for patients with
VAS scores greater or equal to 4. The modified protocol used in this study takes advantage of the known benefits of
ketorolac in the PAI cocktail and postoperative use. Additionally, the modified protocol also uses IV ketorolac at the
end of surgery in the operating room and takes advantage of the postoperative analgesic and antipyretic properties of the
drug [17, 18].
A limitation of this study includes the retrospective nature of the research. Furthermore, this protocol can only be
used in patients  without  contraindications to ketorolac.  The two protocols  were not  studied simultaneously and the
modifications  made  to  the  original  protocol  were  not  made  in  a  stepwise  fashion.  Therefore  it  was  not  possible  to
measure the individual effects of adding postoperative IV ketorolac or removing hydromorphone. Although the study is
well  powered  to  analyze  the  primary  outcomes,  the  study  is  underpowered  to  study  the  possible  complications  of
ketorolac,  none  of  the  patients  in  the  study  had  any  reported  complications  from  ketorolac.  However,  the  use  of
ketorolac is indicated in this population group and recommendations for dosing and length of use were not violated.
CONCLUSION
This  study  reports  how  an  additional  single  dose  of  IV  ketorolac  and  postoperative  oxycodone  instead  of  IV
hydromorphone  in  the  PACU  resulted  in  decreased  incidence  of  postoperative  nausea  without  worsening  average
PACU pain scores. This report demonstrates the need for continuous monitoring of PSH pathways and implementation
of revisions as needed.
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LIST OF ABBREVIATIONS
ASA = Anesthesia score assessment
BMI = Body mass index
PACU = Post acute care unit
PONV = Post operative nausea and vomiting
PSH = Perioperative surgical home
TJR = Total joint replacement
VAS = Visual analog scale
CONFLICT OF INTEREST
RS- Smith & nephew, Intelijoint, Gauss Surgical.
ACKNOWLEDGEMENTS
Declared none.
REFERENCES
[1] Koivuranta M, Lärä E, Snåre L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia 1997; 52(5): 443-9.
[http://dx.doi.org/10.1111/j.1365-2044.1997.117-az0113.x] [PMID: 9165963]
[2] Apfel  CC,  Lärä  E,  Koivuranta  M,  Greim  CA,  Roewer  N.  A  simplified  risk  score  for  predicting  postoperative  nausea  and  vomiting:
conclusions from cross-validations between two centers. Anesthesiology 1999; 91(3): 693-700.
[http://dx.doi.org/10.1097/00000542-199909000-00022] [PMID: 10485781]
[3] Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014;
118(1): 85-113.
[http://dx.doi.org/10.1213/ANE.0000000000000002] [PMID: 24356162]
[4] DiIorio TM, Sharkey PF, Hewitt AM, Parvizi J. Antiemesis after total joint arthroplasty: does a single preoperative dose of aprepitant reduce
nausea and vomiting? Clin Orthop Relat Res 2010; 468(9): 2405-9.
[http://dx.doi.org/10.1007/s11999-010-1357-x] [PMID: 20419358]
[5] Chen JJ, Frame DG, White TJ. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after
total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Arch Intern Med 1998; 158(19):
2124-8.
[http://dx.doi.org/10.1001/archinte.158.19.2124] [PMID: 9801179]
[6] Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo.
Anesthesiology 2000; 92(4): 958-67.
[http://dx.doi.org/10.1097/00000542-200004000-00012] [PMID: 10754614]
[7] Sculco PK, Pagnano MW. Perioperative solutions for rapid recovery joint arthroplasty: get ahead and stay ahead. J Arthroplasty 2015; 30(4):
518-20.
[http://dx.doi.org/10.1016/j.arth.2015.01.036] [PMID: 25680452]
[8] Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J
Med 2004; 350(24): 2441-51.
[http://dx.doi.org/10.1056/NEJMoa032196] [PMID: 15190136]
[9] Tsukada S,  Wakui M, Hoshino A. Postoperative epidural  analgesia compared with intraoperative periarticular injection for pain control
following total knee arthroplasty under spinal anesthesia: a randomized controlled trial. J Bone Joint Surg Am 2014; 96(17): 1433-8.
[http://dx.doi.org/10.2106/JBJS.M.01098] [PMID: 25187581]
[10] Adam F, Chauvin M, Du Manoir B, Langlois M, Sessler DI, Fletcher D. Small-dose ketamine infusion improves postoperative analgesia and
rehabilitation after total knee arthroplasty. Anesth Analg 2005; 100(2): 475-80.
[http://dx.doi.org/10.1213/01.ANE.0000142117.82241.DC] [PMID: 15673878]
[11] Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the
intensive care unit. Crit Care Med 2013; 41(1): 263-306.
[http://dx.doi.org/10.1097/CCM.0b013e3182783b72] [PMID: 23269131]
[12] Strom  BL,  Berlin  JA,  Kinman  JL,  et  al.  Parenteral  ketorolac  and  risk  of  gastrointestinal  and  operative  site  bleeding.  A  postmarketing
surveillance study. JAMA 1996; 275(5): 376-82.
[http://dx.doi.org/10.1001/jama.1996.03530290046036] [PMID: 8569017]
[13] Parvataneni HK, Shah VP, Howard H, Cole N, Ranawat AS, Ranawat CS. Controlling pain after total hip and knee arthroplasty using a
multimodal protocol with local periarticular injections: a prospective randomized study. J Arthroplasty 2007; 22(6)(Suppl. 2): 33-8.
[http://dx.doi.org/10.1016/j.arth.2007.03.034] [PMID: 17823012]
Effects of Modification of Pain Protocol The Open Orthopaedics Journal, 2016, Volume 10   511
[14] Pagnano MW, Hebl J, Horlocker T. Assuring a painless total hip arthroplasty: a multimodal approach emphasizing peripheral nerve blocks. J
Arthroplasty 2006; 21(4)(Suppl. 1): 80-4.
[http://dx.doi.org/10.1016/j.arth.2006.03.001] [PMID: 16781436]
[15] Ali M, Pagnano MW, Horlocker T, Lennon RL. How i manage pain after total hip arthroplasty. Semin Arthroplasty 2008; 19(3): 231-6.
[http://dx.doi.org/10.1053/j.sart.2008.08.003]
[16] Vendittoli PA, Makinen P, Drolet P, et al. A multimodal analgesia protocol for total knee arthroplasty. A randomized, controlled study. J
Bone Joint Surg Am 2006; 88(2): 282-9.
[http://dx.doi.org/10.2106/JBJS.E.00173] [PMID: 16452738]
[17] Koh JC, Lee J, Kim SY, Choi S, Han DW. Postoperative pain and intravenous patient-controlled analgesia-related adverse effects in young
and elderly patients: A retrospective analysis of 10,575 patients. Medicine (Baltimore) 2015; 94(45): e2008.
[http://dx.doi.org/10.1097/MD.0000000000002008]
[18] Thagaard KS, Jensen HH, Raeder J.  Analgesic and antiemetic effect of ketorolac vs.  betamethasone or dexamethasone after ambulatory
surgery. Acta Anaesthesiol Scand 2007; 51(3): 271-7.
[http://dx.doi.org/10.1111/j.1399-6576.2006.01240.x] [PMID: 17257175]
© Schwarzkopf et al.; Licensee Bentham Open
This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License
(CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and
reproduction in any medium, provided the work is properly cited.
